Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Winter;16(1):33-39.
doi: 10.30699/ijp.2020.123998.2353. Epub 2020 Nov 13.

Comparison of Immunohistochemistry Expression of CK7, HMWK and PSA in High-Grade Prostatic Adenocarcinoma and Bladder Transitional Cell Carcinoma

Reza Gheitasi  1   2 , Esmaeil Sadeghi  3 , Mohammad Jafari  4
Affiliations

Comparison of Immunohistochemistry Expression of CK7, HMWK and PSA in High-Grade Prostatic Adenocarcinoma and Bladder Transitional Cell Carcinoma

Reza Gheitasi et al. Iran J Pathol. 2021 Winter.

Abstract

Background & objective: Prostate adenocarcinoma is the most common malignancy in males, and the urothelial bladder carcinoma is also prevalent. The histological characteristic of these two tumors is very similar in high-grade cases, and their differentiation is difficult. This study was performed to compare the immunohistochemistry panel of high-grade prostate adenocarcinomas and high-grade urothelial bladder carcinomas.

Methods: In this cross-sectional study, 36 cases of prostate adenocarcinoma and 36 urothelial bladder carcinoma samples were collected from the pathology department of Shahid Beheshti Hospital in Hamedan. For each sample, expression of Cytokeratin 7, high-molecular-weight cytokeratin and Prostate-specific antigen markers was evaluated by immunohistochemistry. Comparison of expression of these markers in high-grade bladder tumors and prostate tumors was made by SPSS 25 using Chi-square test.

Results: In this study, the Cytokeratin 7 positivity was seen in 88.9% of bladder cancer versus 27.8% of prostate cancer samples. High-molecular-weight cytokeratin positive immunoreactivity was noted in 55.6% of bladder cancer and 5.6% of prostate cancer samples. Prostate-specific antigen marker showed positive results in 94.4% of prostate cancer samples, but no positivity was evident in those of bladder cancer.

Conclusion: A panel of immunohistochemical stains can be used to differentiate high-grade prostate adenocarcinoma from urothelial bladder carcinoma in those cases which are challenging to diagnose.

Keywords: Cytokeratin 7; High-Molecular-Weight Cytokeratin; Prostate Adenocarcinoma; Prostate-Specific Antigen Urothelial Bladder Carcinoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A-D, poorly differentiated transitional cell carcinoma (A, H&E×400), CK7 (B×400), high ‎molecular-weight cytokeratin clone 34βE12 (C×400) and PSA (D×400). E-H, poorly ‎differentiated prostatic carcinoma (E, H&E×400), PSA (F×400), CK7 (G×400) and high-‎molecular-weight cytokeratin clone 34βE12 (H×400).
Fig. 2.
Fig. 2.
Comparison of CK7, HMWK, and PSA expression in Prostate and bladder tumor
See this image and copyright information in PMC

References

    1. Kroft SH, Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Laboratory investigation; a journal of technical methods and pathology. 1994;71(2):158. - PubMed
    1. Benson Jr RC, Tomera KM, Kelalis PP. Transitional cell carcinoma of the bladder in children and adolescents. The Journal of urology. 1983;130(1):54–5. - PubMed
    1. Tomlins SA, Rubin MA. Chinnaiyan AMJARPMD. Integrative biology of prostate cancer progression. 2006;1:243–71. - PubMed
    1. Li M, Cannizzaro LA. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum Pathol. 1999;30(10):1197–200. - PubMed
    1. Bock BJ. Bostwick DGJTAjosp Does prostatic ductal adenocarcinoma exist? 1999;23(7):781. - PubMed

LinkOut - more resources